SPY346.18+4.17 1.22%
DIA284.95+2.92 1.04%
IXIC11,619.47+140.48 1.22%

Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $57

Morgan Stanley maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $55 to $57.

· 10/13/2020 08:06
Morgan Stanley maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $55 to $57.